secwatch.observer — SEC 8-K summary
======================================

Issuer:     Alector, Inc. (ALEC)
CIK:        0001653087
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0000950170-23-005091
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Alector reports Q4 2022 net loss of $52.4M; cash runway through 2025
--------------------------------------------------------------------

- Net loss Q4 2022: $52.4M ($0.63/share) vs $55.6M ($0.68) in Q4 2021; full-year net loss $133.3M ($1.62) vs $36.3M ($0.45).
- Cash, cash equivalents, investments $712.9M as of Dec 31, 2022; management expects runway through 2025.
- 2023 guidance: collaboration revenue $15-25M, R&D expenses $225-245M, G&A expenses $60-70M.
- INVOKE-2 Phase 2 enrollment completion expected Q3 2023, data by Q4 2024; $17.8M milestone from AbbVie triggered.
- INFRONT-3 pivotal trial for latozinemab: regulatory engagement mid-2023, data readout early 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1653087/000095017023005091/0000950170-23-005091-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1653087/000095017023005091/alec-20230228.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-005091

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer